About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Irritable Bowel Syndrome Treatment Market Size, Trends and Growth Analysis by 2033
Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Size, Share & Trends Analysis Report By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, Others), By Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS), By Distribution Channel (Hospitals pharmacies, Drug Stores and Retail Pharmacies, Online pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI55444DR
Last Updated : March 05, 2025
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Irritable Bowel Syndrome Treatment Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Rifaximin
        1. By Value
      3. Eluxadoline
        1. By Value
      4. Lubiprostone
        1. By Value
      5. Linaclotide
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. IBS with Diarrhea (IBS-D)
        1. By Value
      3. IBS with Constipation (IBS-C)
        1. By Value
      4. Mixed IBS
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospitals pharmacies
        1. By Value
      3. Drug Stores and Retail Pharmacies
        1. By Value
      4. Online pharmacies
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Rifaximin
        1. By Value
      3. Eluxadoline
        1. By Value
      4. Lubiprostone
        1. By Value
      5. Linaclotide
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. IBS with Diarrhea (IBS-D)
        1. By Value
      3. IBS with Constipation (IBS-C)
        1. By Value
      4. Mixed IBS
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospitals pharmacies
        1. By Value
      3. Drug Stores and Retail Pharmacies
        1. By Value
      4. Online pharmacies
        1. By Value
    5. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Rifaximin
          1. By Value
        3. Eluxadoline
          1. By Value
        4. Lubiprostone
          1. By Value
        5. Linaclotide
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. IBS with Diarrhea (IBS-D)
          1. By Value
        3. IBS with Constipation (IBS-C)
          1. By Value
        4. Mixed IBS
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospitals pharmacies
          1. By Value
        3. Drug Stores and Retail Pharmacies
          1. By Value
        4. Online pharmacies
          1. By Value
    6. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Rifaximin
        1. By Value
      3. Eluxadoline
        1. By Value
      4. Lubiprostone
        1. By Value
      5. Linaclotide
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. IBS with Diarrhea (IBS-D)
        1. By Value
      3. IBS with Constipation (IBS-C)
        1. By Value
      4. Mixed IBS
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospitals pharmacies
        1. By Value
      3. Drug Stores and Retail Pharmacies
        1. By Value
      4. Online pharmacies
        1. By Value
    5. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Rifaximin
          1. By Value
        3. Eluxadoline
          1. By Value
        4. Lubiprostone
          1. By Value
        5. Linaclotide
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. IBS with Diarrhea (IBS-D)
          1. By Value
        3. IBS with Constipation (IBS-C)
          1. By Value
        4. Mixed IBS
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospitals pharmacies
          1. By Value
        3. Drug Stores and Retail Pharmacies
          1. By Value
        4. Online pharmacies
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Rifaximin
        1. By Value
      3. Eluxadoline
        1. By Value
      4. Lubiprostone
        1. By Value
      5. Linaclotide
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. IBS with Diarrhea (IBS-D)
        1. By Value
      3. IBS with Constipation (IBS-C)
        1. By Value
      4. Mixed IBS
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospitals pharmacies
        1. By Value
      3. Drug Stores and Retail Pharmacies
        1. By Value
      4. Online pharmacies
        1. By Value
    5. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Rifaximin
          1. By Value
        3. Eluxadoline
          1. By Value
        4. Lubiprostone
          1. By Value
        5. Linaclotide
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. IBS with Diarrhea (IBS-D)
          1. By Value
        3. IBS with Constipation (IBS-C)
          1. By Value
        4. Mixed IBS
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospitals pharmacies
          1. By Value
        3. Drug Stores and Retail Pharmacies
          1. By Value
        4. Online pharmacies
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Rifaximin
        1. By Value
      3. Eluxadoline
        1. By Value
      4. Lubiprostone
        1. By Value
      5. Linaclotide
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. IBS with Diarrhea (IBS-D)
        1. By Value
      3. IBS with Constipation (IBS-C)
        1. By Value
      4. Mixed IBS
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospitals pharmacies
        1. By Value
      3. Drug Stores and Retail Pharmacies
        1. By Value
      4. Online pharmacies
        1. By Value
    5. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Rifaximin
          1. By Value
        3. Eluxadoline
          1. By Value
        4. Lubiprostone
          1. By Value
        5. Linaclotide
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. IBS with Diarrhea (IBS-D)
          1. By Value
        3. IBS with Constipation (IBS-C)
          1. By Value
        4. Mixed IBS
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospitals pharmacies
          1. By Value
        3. Drug Stores and Retail Pharmacies
          1. By Value
        4. Online pharmacies
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Rifaximin
        1. By Value
      3. Eluxadoline
        1. By Value
      4. Lubiprostone
        1. By Value
      5. Linaclotide
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. IBS with Diarrhea (IBS-D)
        1. By Value
      3. IBS with Constipation (IBS-C)
        1. By Value
      4. Mixed IBS
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospitals pharmacies
        1. By Value
      3. Drug Stores and Retail Pharmacies
        1. By Value
      4. Online pharmacies
        1. By Value
    5. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Rifaximin
          1. By Value
        3. Eluxadoline
          1. By Value
        4. Lubiprostone
          1. By Value
        5. Linaclotide
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. IBS with Diarrhea (IBS-D)
          1. By Value
        3. IBS with Constipation (IBS-C)
          1. By Value
        4. Mixed IBS
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospitals pharmacies
          1. By Value
        3. Drug Stores and Retail Pharmacies
          1. By Value
        4. Online pharmacies
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Irritable Bowel Syndrome Treatment Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Abbott
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Synergy Pharma
    3. Mallinckrodt
    4. Bausch Health Companies Inc.
    5. Ardelyx
    6. Astellas Pharma Inc.
    7. Novartis AG, GSK plc.
    8. Ironwood Pharmaceuticals, Inc.
    9. Takeda Pharmaceutical Company Limited.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Dry Eye Syndrome Treatment Market Size The global dry eye syndrome treatment market size was valued at USD 4.70 billion in 2022 and is projected to reach USD 7.83 billion by 2031, growing at a CAGR of 5.84% during the forecast pe
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.